Cytokinetics price target raised to $82 from $71 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Cytokinetics (CYTK) to $82 from $71 and keeps an Overweight rating on the shares ahead of aficamten Phase 3 ACACIA data in in nonobstructive hypertrophic cardiomyopathy. The firm sees over a 75% probability of a of positive study given that only one of the dual primary endpoints would need to hit statistical significance. Barclays expects aficamten to become the first approved drug for nonobstructive hypertrophic cardiomyopathy. and preferred drug over Camzyos.